An insight into the interaction between clopidogrel and proton pump inhibitors.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Current drug metabolism

• Publication date

  2012-01-31

• Fields of study

  Medicine

• Identifiers
  DOI 10.2174/138920012798918390PMID 22300021
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Individual variability in the disposition of and response to clopidogrel: pharmacogenomics and beyond.

  2011cited by this paper
• Clopidogrel and proton pump inhibitors: influence of pharmacological interactions on clinical outcomes and mechanistic explanations.

  2011cited by this paper
• Aspirin and clopidogrel resistance: methodological challenges and opportunities

  2010cited by this paper
• Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor.

  2010cited by this paper
• Impact of Proton Pump Inhibitors on the Effectiveness of Clopidogrel After Coronary Stent Placement: The Clopidogrel Medco Outcomes Study

  2010cited by this paper
• Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel.

  2010cited by this paper
• Clopidogrel with or without omeprazole in coronary artery disease.

  2010cited by this paper
• Potentiation of clopidogrel active metabolite formation by rifampicin leads to greater P2Y12 receptor blockade and inhibition of platelet aggregation after clopidogrel

  2010cited by this paper
• Metabolism and Disposition of the Thienopyridine Antiplatelet Drugs Ticlopidine, Clopidogrel, and Prasugrel in Humans

  2010cited by this paper
• Identification of the Human Cytochrome P450 Enzymes Involved in the Two Oxidative Steps in the Bioactivation of Clopidogrel to Its Pharmacologically Active Metabolite

  2010cited by this paper
• Outcomes With Concurrent Use of Clopidogrel and Proton-Pump Inhibitors

  2010cited by this paper
• Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placement

  2010cited by this paper
• Impact of genetic polymorphisms and drug-drug interactions on clopidogrel and prasugrel response variability.

  2010cited by this paper
• Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17.

  2010cited by this paper
• Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials.

  2009cited by this paper
• Genetic determinants of response to clopidogrel and cardiovascular events.

  2009cited by this paper
• Multiple mechanisms affect the clopidogrel response.

  2009cited by this paper
• Cytochrome p-450 polymorphisms and response to clopidogrel.

  2009cited by this paper
• A population-based study of the drug interaction between proton pump inhibitors and clopidogrel

  2009cited by this paper
• Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel.

  2009cited by this paper
• Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel

  2009cited by this paper
• Cardiovascular Outcomes and Mortality in Patients Using Clopidogrel With Proton Pump Inhibitors After Percutaneous Coronary Intervention or Acute Coronary Syndrome

  2009cited by this paper
• The Effect of CYP2C19 Polymorphism on the Pharmacokinetics and Pharmacodynamics of Clopidogrel: A Possible Mechanism for Clopidogrel Resistance

  2008cited by this paper
• Effects of the Proton Pump Inhibitor Lansoprazole on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel

  2008cited by this paper
• Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome.

  2008cited by this paper
• Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.

  2008cited by this paper
• ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents.

  2008cited by this paper
• Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors.

  2008cited by this paper
• CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation.

  2008cited by this paper
• Calcium channel blockers reduce the antiplatelet effect of clopidogrel

  2008cited by this paper
• Aspirin and clopidogrel response variability: review of the published literature.

  2008cited by this paper
• ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use

  2008cited by this paper
• Pharmacogenetics of Oral Anticoagulants

  2008cited by this paper
• Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers.

  2008cited by this paper
• High-dose atorvastatin does not negatively influence clinical outcomes among clopidogrel treated acute coronary syndrome patients--a Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) analysis.

  2008cited by this paper
• Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study.

  2008cited by this paper
• Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel.

  2008cited by this paper
• Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease.

  2007cited by this paper
• Prasugrel versus clopidogrel in patients with acute coronary syndromes.

  2007cited by this paper
• A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease.

  2007cited by this paper
• Cytochrome P450 3A Inhibition by Ketoconazole Affects Prasugrel and Clopidogrel Pharmacokinetics and Pharmacodynamics Differently

  2007cited by this paper
• Clopidogrel resistance?

  2007cited by this paper
• Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel

  2007cited by this paper
• Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives.

  2007cited by this paper
• Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study.

  2007cited by this paper
• Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin

  2006cited by this paper
• A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants

  2006cited by this paper
• Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel

  2006cited by this paper
• Resistance to clopidogrel: a review of the evidence.

  2005cited by this paper
• Clopidogrel resistance: a new chapter in a fast-moving story.

  2004cited by this paper
• Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study.

  2004cited by this paper
• Contribution of Hepatic Cytochrome P450 3A4 Metabolic Activity to the Phenomenon of Clopidogrel Resistance

  2004cited by this paper
• Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.

  2004cited by this paper
• Atorvastatin Reduces the Ability of Clopidogrel to Inhibit Platelet Aggregation: A New Drug–Drug Interaction

  2003cited by this paper
• Platelet activation after stenting with heparin-coated versus noncoated stents.

  2003cited by this paper
• Lack of Adverse Clopidogrel–Atorvastatin Clinical Interaction From Secondary Analysis of a Randomized, Placebo-Controlled Clopidogrel Trial

  2003cited by this paper
• Clopidogrel for Coronary Stenting Response Variability, Drug Resistance, and the Effect of Pretreatment Platelet Reactivity

  2003cited by this paper
• Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement

  2003cited by this paper
• Structure and stereochemistry of the active metabolite of clopidogrel.

  2002cited by this paper
• Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.

  2002cited by this paper
• Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.

  2001cited by this paper
• Genetic and Environmental Contributions to Platelet Aggregation: The Framingham Heart Study

  2001cited by this paper
• Identification and Biological Activity of the Active Metabolite of Clopidogrel

  2000cited by this paper
• Identification of the human P450 enzymes involved in lansoprazole metabolism.

  1996cited by this paper
• The Antiaggregating Activity of Clopidogrel Is due to a Metabolic Activation by the Hepatic Cytochrome P450-1A

  1994cited by this paper

• Evaluation of CYP2C19 activity using microdosed oral omeprazole in humans

  2022cites this paper
• Efficacy and safety of proton pump inhibitors combined with clopidogrel in patients undergoing percutaneous coronary intervention: a meta-analysis.

  2021cites this paper
• Coding SNPs in hsa-miR-1343-3p and hsa-miR-6783-3p target sites of CYP2C19 modulates clopidogrel response in individuals with cardiovascular diseases.

  2020cites this paper
• Nonsteroidal anti-inflammatory drug choice and adverse outcomes in clopidogrel users: A retrospective cohort study

  2018cites this paper
• Polymorphisms in cytochrome P450 oxidoreductase and its effect on drug metabolism and efficacy

  2017cites this paper
• Is the concomitant use of clopidogrel and Proton Pump Inhibitors still associated with increased adverse cardiovascular outcomes following coronary angioplasty?: a systematic review and meta-analysis of recently published studies (2012 – 2016)

  2017cites this paper
• Impact of concomitant use of proton pump inhibitors and clopidogrel or ticagrelor on clinical outcomes in patients with acute coronary syndrome

  2016cites this paper
• The CYP 2 C 19 Intron 2 Branch Point SNP is the Ancestral Polymorphism Contributing to the Poor Metabolizer Phenotype in Livers with CYP 2 C 19 * 35 and CYP 2 C 19 * 2 Alleles s

  2015cites this paper
• Interindividual variability of CYP2C19-catalyzed drug metabolism due to differences in gene diplotypes and cytochrome P450 oxidoreductase content

  2015cites this paper
• Pharmacokinetic drug interactions with clopidogrel: updated review and risk management in combination therapy

  2015cites this paper
• The CYP2C19 Intron 2 Branch Point SNP is the Ancestral Polymorphism Contributing to the Poor Metabolizer Phenotype in Livers with CYP2C19*35 and CYP2C19*2 Alleles

  2015cites this paper
• Comparative Risk of Ischemic Stroke Among Users of Clopidogrel Together With Individual Proton Pump Inhibitors

  2015influential citation
• Antiplatelet drug interactions with proton pump inhibitors

  2014cites this paper
• The discovery and development of prasugrel

  2013cites this paper
• FREQUENCY OF DUAL ANTI PLATELET RESISTANCE IN PATIENTS WITH CORONARY ARTERY DISEASE

  2013cites this paper
• Evaluation of Six Proton Pump Inhibitors as Inhibitors of Various Human Cytochromes P450: Focus on Cytochrome P450 2C19

  2012cites this paper
• Evaluation of Six Proton Pump Inhibitors As Inhibitors of Various Human Cytochromes P450: Focus on Cytochrome P450 2C19

  2012cites this paper
• [Three case reports of the use of herbal combinations resulted in stent thrombosis: herbal combinations; friend or foe?].

  2012cites this paper
• Bitkisel karişim kullanan ve stent trombozu gelişen üç olgu: Bitkisel karişimlar dost mu, düşman mi? Three case reports of the use of herbal combinations resulted in stent thrombosis: herbal combinations; friend or foe?

  2012cites this paper
• Evaluation of Six Proton Pump Inhibitors as Inhibitors of Various Human Cytochromes P450: Focus on Cytochrome P450 2C19

  2012cites this paper